Cellectar Biosciences is partnering with Florida Cancer Specialists & Research Institute (FCS) to advance patient care and further define the U.S. treatment landscape, the company announced today.

According to a release, the biotech company and FCS will evaluate and further define unmet needs that exist across the Waldenstrom’s Macroglobulinemia (WM) treatment landscape within the community oncology setting to advance patient care.

“We are extremely pleased to be partnering with FCS, which shares our patient-centric vision and alignment on the unique benefits and significant potential of radiotherapeutics,” Cellectar Biosciences CEO James Caruso said in a statement. “This collaboration will help us to better understand patients’ and healthcare providers’ needs across the WM treatment landscape.”

Cellectar looks to release data from its CLOVER-WaM pivotal trial in WM in Q4 of this year and remains on target for a 2024 U.S. product launch.